Valuation : Telix Pharmaceuticals Limited

Market Cap 5.32B 3.82B 3.29B 3.12B 2.82B 5.3B 365B 37B 14.23B 186B 14.34B 14.03B 586B P/E 2026 *
230x
P/E 2027 * 205x
Enterprise Value 5.75B 4.13B 3.55B 3.37B 3.05B 5.72B 394B 39.97B 15.37B 200B 15.49B 15.15B 634B EV / Sales 2026 *
4.21x
EV / Sales 2027 * 3.7x
Free-Float
83.1%
Yield 2026 *
-
Yield 2027 * -
1 day-6.50%
1 week-4.86%
Current month+2.02%
1 month-7.55%
3 months+16.33%
6 months+45.63%
Current year+39.91%
1 week 15.5
Extreme 15.5
17
1 month 14.86
Extreme 14.86
18.13
Current year 8.26
Extreme 8.26
18.13
1 year 8.26
Extreme 8.26
18.32
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
5/26/26 A Free

Director

21,597 0.0064%
5/26/26 A Free

Founder

339,845 0.1001%
5/26/26 A Free

Director

21,597 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-6.50%-4.86%+13.72%+38.55% 4.08B
-0.71%-6.35%-4.87%+9.03% 46.05B
+0.21%-2.98%+340.68%+519.93% 43.59B
+1.74%-2.24%+37.28%+21.57% 42.35B
+1.38%-3.28%+3.23%+65.60% 38.86B
-1.44%-5.26%+8.78%+36.85% 32.24B
+0.87%-2.60% - - 17.16B
+0.75%-0.64%+18.07%+110.32% 16.28B
-0.31%-2.78%+10.47%+30.49% 14.32B
+1.93%-3.55%+74.20%+39.37% 13.03B
Average -0.21%-3.50%+55.73%+96.86% 26.8B
Weighted average by Cap. +0.29%-4.39%+72.08%+122.13%

Financials

2026 *2027 *
Net sales 1.37B 979M 844M 799M 724M 1.36B 93.56B 9.49B 3.65B 47.6B 3.68B 3.6B 150B 1.57B 1.13B 973M 921M 835M 1.57B 108B 10.94B 4.21B 54.88B 4.24B 4.15B 173B
Net income 24.95M 17.9M 15.42M 14.6M 13.23M 24.83M 1.71B 173M 66.69M 870M 67.22M 65.74M 2.75B 13.79M 9.89M 8.52M 8.07M 7.32M 13.72M 945M 95.85M 36.86M 481M 37.15M 36.34M 1.52B
Net Debt 427M 306M 264M 250M 227M 425M 29.27B 2.97B 1.14B 14.89B 1.15B 1.13B 47.05B 495M 355M 306M 289M 262M 492M 33.88B 3.44B 1.32B 17.24B 1.33B 1.3B 54.47B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
11/09/26 A$15.67 -6.50% 2,193,327
10/09/26 A$16.76 +0.42% 1,759,963
09/09/26 A$16.69 +1.15% 1,109,874
08/09/26 A$16.50 +1.54% 1,119,678
07/09/26 A$16.25 -1.34% 1,122,950
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
15.67AUD
Average target price
23.72AUD
Spread / Average Target
+51.39%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!